Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
26 juil. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Want the All-Canadian experience of the second-round playoffs without the expense? Shark Club Sports Bar & Grill is ready to welcome you
10 mai 2024 17h30 HE
|
Shark Club Sports Bar & Grill
VANCOUVER, British Columbia, May 10, 2024 (GLOBE NEWSWIRE) -- Shark Club Sports Bar and Grill has set a new standard for sports bars. Its downtown Vancouver location boasts not one but two 12-foot x...
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
27 avr. 2023 07h01 HE
|
Autolus Therapeutics plc
LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics to Host Virtual Capital Markets Day
25 avr. 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a...
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
09 août 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress
11 juin 2021 07h00 HE
|
Autolus Therapeutics plc
Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade...
Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies
08 déc. 2019 09h15 HE
|
Autolus Therapeutics plc
Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T 90% complete response and 100% overall survival at 12 months in CAR T naive pediatric ALL...
Autolus Therapeutics and Noile-Immune Announce Licensing Agreement
13 nov. 2019 06h30 HE
|
Autolus Therapeutics plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune...
Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL
03 sept. 2019 02h00 HE
|
Autolus Therapeutics plc
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete...
Autolus Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
08 août 2019 07h49 HE
|
Autolus Therapeutics plc
LONDON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...